Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer

NCT01637532 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Ovarian Cancer

Interventions

DRUG: tocilizumab and interferon alpha 2-b
DRUG: Carboplatin and Caelyx or doxorubicin

Sponsor

Leiden University Medical Center

Collaborators

[object Object]